NCT07200193View on ClinicalTrials.gov

A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

66

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 31, 2032

Study Completion Date

December 31, 2032

Conditions

Chronic Hepaititis B

Interventions

GENETIC

CRMA-1001

Epigenetic gene silencing therapy delivered by intravenous (IV) infusion

Sponsors

Lead Sponsor

All Listed Sponsors

lead

nChroma Bio

INDUSTRY